Kauliv

Teriparatide, the active ingredient in Kauliv, is a parathyroid hormone (PTH) analog presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of osteoporosis in patients at high risk of fracture, including postmenopausal women, men, and individuals with glucocorticoid‑induced bone loss.

GNH USA supplies Kauliv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution.

Teriparatide is a bone anabolic agent used in the management of osteoporosis and related conditions.

Postmenopausal osteoporosis: increases bone mineral density and reduces fracture risk in women at high risk. Osteoporosis in men: improves bone strength and lowers incidence of vertebral and non‑vertebral fractures. Glucocorticoid‑induced osteoporosis: restores bone formation and mitigates steroid‑related bone loss.

Teriparatide may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Nausea - Headache - Dizziness - Injection site pain or erythema - Hypercalcemia - Leg cramps

Serious or Rare Side Effects: - Osteosarcoma (observed in animal studies) - Severe hypercalcemia - Anaphylactic or severe hypersensitivity reactions - Hypotension or syncope - Severe injection‑site infection - Cardiovascular events such as arrhythmia

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant parameters.

Renal function: assess baseline kidney function and monitor during treatment. Hypercalcemia: check serum calcium levels before and periodically after starting. History of skeletal malignancy: avoid use in patients with prior bone cancer. Pregnancy and lactation: use only if potential benefits outweigh risks. Duration of therapy: limit to the period recommended by clinical guidelines. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Teriparatide can interact with other agents that affect calcium balance or bone metabolism.

Major Interactions (Avoid): - Calcium supplements or high‑dose vitamin D: may increase risk of hypercalcemia. - Bisphosphonates administered concurrently: can blunt the anabolic effect of teriparatide.

Moderate Interactions (Monitor Closely): - Corticosteroids: may reduce therapeutic response, requiring closer monitoring. - Anticonvulsants (e.g., phenytoin, phenobarbital): can affect bone turnover and calcium levels. - Warfarin: monitor INR as changes in bone metabolism may influence anticoagulation stability.